Vincerx Pharma Inc. (VINC)
0.15
-0.02 (-12.13%)
At close: Jan 15, 2025, 3:59 PM
0.16
5.05%
After-hours Jan 15, 2025, 07:42 PM EST
Company Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer.
The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.
Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Vincerx Pharma Inc.
| Country | United States |
| IPO Date | May 27, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Dr. Raquel E. Izumi Ph.D. |
Contact Details
Address: 260 Sheridan Avenue Palo Alto, California United States | |
| Website | https://vincerx.com |
Stock Details
| Ticker Symbol | VINC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001796129 |
| CUSIP Number | 92731L106 |
| ISIN Number | US92731L1061 |
| Employer ID | 83-3197402 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raquel E. Izumi Ph.D. | Co-Founder, Acting Chief Executive Officer, Secretary & Director |
| Kevin Haas | Acting Chief Financial Officer, Vice President of Finance & Corporate Controller |
| Tom C. Thomas J.D. | Founder, General Counsel & Chief Legal Officer |
| Dr. Ahmed M. Hamdy M.D. | Co-Founder & Chairman |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer |
| Dr. John C. Byrd M.D. | Founder & Chairman of Scientific Advisory Board |
| Gabriela Jairala | Vice President of Investor Relations & Corporate Communications and Chief of Staff |
| Karen Quarford M.B.A. | Vice President of Quality Operations & Compliance |
| Melissa Merrick SPHR | Senior Director of People & Culture and Head of Human Resource |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 3 | Filing |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 27, 2024 | 424B5 | Filing |
| Dec 10, 2024 | DEF 14A | Filing |
| Dec 06, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |